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INTERLEUKIN-18 REDUCES BLOOD GLUCOSE AND 
MODULATES PLASMA CORTICOSTERONE IN A SEPTIC 
MOUSE MODEL 
 
ABSTRACT 
Background: Dysregulation of glucose metabolism, including hyperglycemia with 
insulin resistance, is commonly observed in critically ill patients. Interleukin-18 (IL-18) 
improves the insulin resistance associated with obesity, but the relationship between 
IL-18 and glucose metabolism in sepsis was unclear. The purpose of this study was to 
investigate the influence of IL-18 on hyperglycemia during sepsis. Methods: Sepsis was 
induced using cecal ligation and puncture (CLP) in wild-type (WT) mice, IL-18 knockout 
(KO) mice, and IL-18 KO mice pretreated with recombinant IL-18. Blood glucose and 
plasma insulin, glucagon, and corticosterone were measured. The mRNAs for 
gluconeogenic enzymes (g6pc, pck1) and activation of insulin signaling were also 
analyzed. Results: In both WT and IL-18 KO mice, CLP operation led to hyperglycemia 
that lasted longer (18 h) than after sham operation (6 h). Blood glucose levels in IL-18 
KO mice were significantly higher than in WT mice, without alteration of insulin or 
glucagon levels. In IL-18 KO mice, insulin signaling in the liver and skeletal muscle was 
decreased during hyperglycemia as compared with WT mice without suppression of 
hepatic glucose production enzymes. Pretreatment with recombinant IL-18 reduced 
blood glucose levels after CLP. Additionally, corticosterone levels were higher after CLP 
in the presence of either endogenous or exogenous IL-18. Conclusion: IL-18 may reduce 
blood glucose by modulating insulin signaling in the liver during sepsis-induced 
hyperglycemia. IL-18 is an important factor associated with alterations in blood glucose 
during sepsis. 
KEYWORDS—Glucocorticoid, hyperglycemia, IL-18, insulin resistance, sepsis  
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Introduction 
Dysregulation of glucose metabolism is a cause of poor outcomes in critically 
ill patients, including patients with sepsis, independent of whether or not the patient is 
diabetic (1,2). Under septic conditions, adrenaline, glucagon, and glucocorticoids are 
increased and lead to hyperglycemia via gluconeogenesis and glycogenolysis in the liver. 
Pro-inflammatory cytokines, including tumor necrosis factor -α and interleukin (IL)-6, 
are elevated and inhibit insulin signaling pathways in the liver and peripheral tissues (3,4). 
Thus, septic patients exhibit poor glycemic control, hyperglycemia, and transient insulin 
resistance. Controlling blood glucose levels improves the prognosis of septic patients. 
However, because hypoglycemia is a strong risk factor for death in critically ill patients, 
blood glucose control should be attempted with care (5). The 2012 Surviving Sepsis 
Campaign guidelines state that blood glucose should be controlled to be lower than 180 
mg/dL (rather than <110 mg/dL) to reduce the risk of inducing hypoglycemia (6).  
IL-18 is a pro-inflammatory cytokine secreted by T-cells, macrophages, 
Kupffer cells, monocytes, dendritic cells, keratinocytes, intestinal epithelial cells, the 
pituitary gland, and the adrenal cortex (7-9). During sepsis, the production of endogenous 
IL-18 is increased, and increases in circulating IL-18 correlate with the severity of the 
disease (10-11). In fact, urinary IL-18 levels are a potentially useful biomarker for acute 
kidney injury during sepsis (12). Additionally, septic patients suffering acute respiratory 
distress syndrome (ARDS) had higher plasma IL-18 levels than septic patients without 
ARDS (13). In our previous report, which was the first report focusing on IL-18 and 
transient insulin resistance mediated by acute inflammation, we found that endogenous 
IL-18 attenuated transient hyperglycemia by enhancing hepatic insulin signaling during 
the hyperacute phase of lipopolysaccharide (LPS)-induced lethal endotoxemia (14).  
Increases in circulating IL-18 predict the development of insulin resistance in 
patients with diabetes and obesity (15,16). Paradoxically however, experimental studies 
have shown that endogenous and exogenous IL-18 can mitigate insulin resistance (17,18). 
IL-18 enhances insulin signaling, such as Akt phosphorylation, in the liver and skeletal 
muscles in obese mice (18). However, there are few reports on the relationship between 
IL-18 and insulin signaling during sepsis. IL-18 may be a useful predictor or therapeutic 
target in controlling blood glucose in sepsis if the role of IL-18 in sepsis-induced transient 
insulin resistance or sepsis-induced hyperglycemia is better understood. We hypothesized 
that IL-18 suppresses sepsis-induced hyperglycemia via maintenance of insulin signaling 
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in the liver and skeletal muscle. To test this hypothesis, we used a mouse model of sepsis 
induced by cecal ligation and puncture (CLP), which is known to closely reflect the 
clinical situation of critically ill patients (19).  
 
Methods 
Animals 
Nine to 12-week old, male C57BL/6J (wild type, WT) mice (Clea Japan, Tokyo, 
Japan) and IL-18 knockout (KO) mice (B6.129P2-IL18
tm1Aki
/J; The Jackson Laboratory, 
Bar Harbor, ME) were used in this study. The body weights of the WT mice and IL-18 
KO mice were similar at the start of the study (25.3±1.2 g and 24.8±1.0 g, respectively). 
All mice were kept at 22±2°C under a 12 hour light/dark cycle and allowed access to a 
standard diet and water ad libitum. All experiments involving mice were conducted with 
the approval of the Animal Care and Use Committee of Kobe University.  
 
Sepsis model by cecal ligation and puncture  
Sepsis was induced by cecal ligation and puncture (CLP) under anesthesia (0.3 
mg/kg medetomidine, 4.0 mg/kg midazolam, 5.0 mg/kg butorphanol), and the operations 
were performed between 8:00 am and 10:00 am in all mice. Through a 1 cm abdominal 
midline incision, the cecum was ligated with 3-0 silk suture and punctured with an 
18-gauge needle in a through-and-through manner. The abdominal wall and skin were 
closed with 5-0 nylon suture in two layers. Sham-operated mice underwent laparotomy 
without ligation or puncture. All animals were subcutaneously given 40 mL/kg saline 
(37 °C) immediately after the surgery for fluid resuscitation. Prior to surgery (0 hours) 
and 6, 12, or 24 hours after surgery, the mice were sacrificed by cardiac puncture under 
general anesthesia. Samples of blood and tissue were immediately harvested, placed in 
the reagent necessary for the next experiment, and stored at -80°C.  
When examining glucose tolerance, a “mild” CLP procedure was performed, 
that mimicked the standard CLP procedure for inducing sepsis except for the use of a 
21-gauge needle rather than an 18-gauge needle for puncture. Glucose-tolerance tests in 
mice subjected to the standard CLP protocol were very difficult to perform and to 
interpret because the WT mice were close to death when blood glucose levels returned to 
the baseline after CLP. Thus, we chose to perform the glucose-tolerance tests in mice 
subjected to a less intense CLP protocol. 
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Blood analysis 
Blood glucose and plasma corticosterone were measured in tail vein blood to 
minimize the influence of repeated stress. For the measurement of other parameters, 
blood samples were obtained by cardiac puncture. Blood glucose levels were measured 
using a portable glucose meter (Glutest NEO Sensor; Sanwa Kagaku Kenkyusho, Nagoya, 
Japan). Plasma insulin (Shibayagi, Gunma, Japan), glucagon (WAKO, Osaka, Japan), 
corticosterone (AssayPro, St. Charles, MO), IL-18 (MBL, Nagoya, Japan), and IL-6 
(R&D Systems, Minneapolis, Minnesota) were measured using enzyme-linked 
immunosorbent assay (ELISA) kits according to the manufacturers’ instructions.  
Real-time reverse transcription PCR 
Total RNA were extracted by TRIzol® Reagent (Invitrogen, Carlsbad, CA), and the 
cDNA was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA) according to the manufacturer’s instructions. The following cDNAs were 
then quantified with quantitative real-time RT-PCR analysis using SYBR Green Realtime 
PCR Master Mix (Toyobo, Osaka, Japan) and the primers indicated: 
glucose-6-phosphatase gene (g6pc, F: tgctgtgtctggtaggcaac, R: agaatcctgggtctccttgc), 
phosphoenolpyruvate carboxykinase gene (pck1, F: agcctgctccagctttga, R: 
ccctagcctgttctctgtgc), and glucokinase (gck, F: ggtgagctggacgagtt, R: 
aagattctcctctaccagctt). Relative expression of each cDNA was calculated using the ddCt 
method after normalization to glyceraldehyde 3-phosphate dehydrogenase (gapdh, F: 
tgtgtccgtcgtggatctga, R: ttgctgttgaagtcgcaggag) expression. 
 
Western blotting 
Anti-Akt and anti-Ser473 phosphorylated Akt were purchased from Cell 
Signaling Technology (Danvers, MA). Anti-β-actin antibody was obtained from 
Sigma-Aldrich (St Louis, MO). The liver and gastrocnemius muscle (skeletal muscle) 
samples were homogenized in lysis buffer (100 mM HEPES (pH 7.4), 1% Triton, 10% 
glycerol, 150 mM NaCl, 1 mM sodium pyrophosphate, 100 mM sodium fluoride, 2 mM 
EDTA, 5 mM sodium vanadate, 1 mM PMSF, 5 μg/mL aprotinin, and 5 μg/mL leupeptin). 
Western blotting was performed as described previously (14). Membranes were 
incubated overnight at 4°C with primary antibodies diluted in Can Get Signal 
immunoreaction enhancer solution 1 (Toyobo), then with horseradish 
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peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA) diluted in Can Get Signal solution 2 (Toyobo) for 1 hour 
at room temperature. Antibody binding was detected using enhanced chemiluminescence 
plus reagents (GE Healthcare, Buckinghamshire, UK) and the Optima Shot CL-420a 
image-capturing system (Wako, Osaka, Japan). The band intensity was quantified using 
ImageJ ver. 1.47 (U. S. National Institutes of Health, Bethesda, Maryland).  
 
Intraperitoneal glucose tolerance test 
WT and IL-18 KO mice were intraperitoneally injected 2 g/kg D-glucose in 20 
mL/kg saline at 20 hours after mild CLP. Blood glucose levels were measured using tail 
vein blood before (0 minutes) and 15, 30, 60, 120, and 240 minutes after mild CLP. 
 
Recombinant IL-18 administration to IL-18 KO mice 
IL-18 KO mice were injected with 1 μg recombinant mouse IL-18 (rIL-18; 
MBL, Nagoya, Japan) in 0.2 mL phosphate buffered saline (PBS) intraperitoneally 24 
hours, 4 hours and 0.5 hours before the CLP operation. This dose of recombinant IL-18 
was determined in a previous study (17). Blood glucose, plasma insulin, and plasma 
corticosterone were then measured using tail vein blood 0, 6, 12, 24 hours after CLP. Five 
mice per group were sacrificed 12 and 24 hours after CLP to analyze Akt phosphorylation 
in the liver and skeletal muscle.  
 
Statistical analysis 
The data were expressed as mean ± standard error of the mean. Survival was 
examined by Kaplan-Meier analysis and the log-rank test. T-tests were performed for 
examining the elevation of IL-18 after CLP. Two-factor analysis of variance (ANOVA) 
was performed for the time course experiments comparing WT and IL-18 KO mice. For 
other experiments, ANOVA with the Tukey-Kramer’s post hoc test was performed. A 
probability level of p<0.05 was considered statistically significant. 
 
Results 
Mortality and plasma cytokine levels after CLP  
 The mortality in this septic model tended to higher in the WT mice (81.3%) as 
compared with IL-18 KO mice (47.1%), but this difference was not statistically 
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significant (p=0.069) (Fig. 1A). In WT mice, plasma IL-18 levels were elevated 
significantly 6 and 24 hour after CLP. As expected, IL-18 could not be detected in the 
IL-18 KO mice (Fig. 1B). IL-6 levels were elevated after CLP in a time-dependent 
manner, with no differences between the WT and IL-18 KO mice (Fig. 1C). There were 
no significant differences in multiple biochemical markers in the blood in response to 
either CLP operation or IL-18 status. (Supplemental Table 1) When lung, liver, and 
kidney morphology was examined after CLP, only minor differences in neutrophil 
accumulation were seen between the lungs of WT and IL-18 KO mice (Supplemental 
Figure 1). CLP-induced sepsis led to injury in the liver and kidney with no differences 
between the WT and IL-18 KO mice (data not shown). 
 
Blood glucose and plasma hormones 
To assess the effects of IL-18 on glucose metabolism, we measured blood 
glucose, insulin, glucagon, and corticosterone in WT and IL-18 KO mice after inducing 
sepsis using CLP or after a sham operation. Sham operation induced transient 
hyperglycemia in both WT and IL-18 KO mice for 6 hours, and then the blood glucose 
levels decreased, and the mice recovered glucose homeostasis within 15 hours after the 
sham operation. The hyperglycemic period was prolonged by CLP in both WT and IL-18 
KO mice, and blood glucose was still high 18 hours after CLP (Fig. 2A). In addition, CLP 
lead to the difficulty in maintaining glucose homeostasis. During the first 24 hours after 
CLP, the blood glucose levels in IL-18 KO mice were significantly higher than in WT 
mice (p<0.01). By 24 hours after CLP, most of the WT mice developed hypoglycemia 
(<70 mg/dL glucose) (66.7%; 4/6), but the IL-18 KO mice did not (0%; 0/6). Plasma 
insulin levels were decreased 6 to 12 hours after CLP then sharply increased 24 hours 
after CLP in both WT and IL-18 KO mice (Fig. 2B). The plasma glucagon profile was 
also not significant altered by IL-18 deficiency (Fig. 2C). Plasma corticosterone levels 
were elevated after CLP, and the levels in IL-18 KO mice were significantly lower than 
those in WT mice 24 hours after CLP (Fig. 2D, p<0.05).  
 
Gluconeogenic enzyme mRNA expression in the liver 
Because gluconeogenesis and glycogenolysis in the liver increase adrenaline, 
glucagon, and glucocorticoid levels leading to hyperglycemia in septic patients, we 
examined the effects of IL-18 deletion on the glucose metabolism in the liver by 
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examining the expression of the mRNAs for gluconeogenic and glycolytic enzymes. 
G6pc and pck1 (gluconeogenic enzymes) were transiently increased and then decreased 
after CLP, but no significant differences existed between WT and IL-18 KO mice (Fig. 
3A, B). Gck (a glycolytic enzyme) was consistently decreased by CLP, and there were no 
significant differences in the WT and IL-18 KO mice (Fig. 3C). These results suggested 
that IL-18 modulation of blood glucose levels during sepsis was not a result of either 
gluconeogenesis or glycogenolysis in the liver.  
 
Insulin signaling in the liver and skeletal muscle 
To assess the effects of IL-18 deletion on insulin signaling in response to acute 
inflammation, we analyzed the activation of Akt. We assessed Akt phosphorylation 
(pAkt) 6 and 24 hours after CLP because a difference in blood glucose between IL-18 KO 
and WT mice was first observed 6 hours after CLP and 24 hours marked the lowest blood 
glucose levels after CLP. In the liver and skeletal muscle of WT mice, pAkt levels were 
decreased 6 hours after CLP, but recovered to baseline levels within 24 hours (Fig. 4). In 
IL-18 KO mice, pAkt expression was significantly lower than in WT mice before CLP 
and 6 hours after CLP, but was significantly higher 24 hours after CLP in both the liver 
and skeletal muscle.  
 
Glucose clearance after CLP 
To determine the effect of IL-18 deletion on the glucose clearance, we 
performed intraperitoneal glucose tolerance tests after inducing sepsis using a milder 
CLP procedure. Glucose clearance was significantly impaired in the IL-18 KO mice as 
compared with the WT mice (Fig. 5, p<0.05). 
 
The effects of exogenous IL-18  
To test whether the marked increase in blood glucose levels in response to CLP 
in IL-18 KO mice could be attenuated by exogenous IL-18, we administered rIL-18 to 
IL-18 KO mice before the CLP operation. Administration of rIL-18 before CLP 
remarkably reduced blood glucose levels 12 hours after CLP in IL-18 KO mice (Fig. 6A) 
as compared with control mice given PBS. Plasma insulin was increased 12 and 24 hours 
after CLP regardless of rIL-18 pretreatment (Fig. 6B). Plasma corticosterone levels 
increased 12 and 24 hours after CLP regardless of rIL-18 pretreatment, but the increase in 
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rIL-18-pretreated IL-18 KO mice was significantly higher than in PBS-treated IL-18 KO 
mice (Fig. 6C, p<0.05). Akt phosphorylation in the liver was increased by 
rIL-18-treatment (Fig. 6D); Akt phosphorylation was not increased in the skeletal 
muscle.  
 
Discussion 
This study showed that IL-18 influences blood glucose levels during 
sepsis-induced hyperglycemia. The mechanisms underlying IL-18 modulation of blood 
glucose levels was independent of insulin- and glucagon-dependent regulatory systems. 
Corticosterone, which is a main glucocorticoid in rodents, might be modulated by IL-18 
during sepsis because corticosterone levels were decreased in the absence of IL-18 and 
increased when rIL-18 was administered. In addition, deletion of IL-18 prolonged insulin 
signaling in the liver and skeletal muscle, but did not influence gluconeogenesis or 
glycogenolysis during hyperglycemia. Thus, IL-18 may improve the uptake of glucose by 
the tissues and help maintain plasma glucocorticoid levels during sepsis-induced 
hyperglycemia.    
Our finding here of higher blood glucose levels in IL-18 KO mice after 
CLP-induced sepsis was similar to the findings of our previous study using LPS-induced 
endotoxemia in mice (14). The result was also supported by Akt activation in the liver and 
skeletal muscle and the slower glucose clearance in IL-18 KO mice compared with WT 
mice shown in this study. IL-18 may decrease blood glucose by modulating insulin 
signaling in multiple tissues. The finding that blood glucose levels after CLP are reduced 
when IL-18 KO mice were treated with recombinant IL-18 strengthened this notion.  
The influence of IL-18 on liver function may be small. In this study, 
gluconeogenic enzymes were not altered by IL-18 status. In studies of obesity and 
diabetes, IL-18 was found to be involved in energy homeostasis, including food intake, 
glucose tolerance disorder, and fatty acid oxidation (17,18). The current study suggests 
that IL-18 may regulate glucose homeostasis during critical illness without suppression 
of hepatic glucose synthesis. The plasma insulin levels in this study were not high enough 
to be classified as hyperinsulinemia, whereas in our previous study, hyperinsulinemia 
accompanied hyperglycemia in IL-18 KO mice with LPS-induced endotoxemia. The fact 
that sepsis was induced by an abdominal surgery procedure in the CLP model may be the 
cause of this difference. Insulin secretion from rat pancreatic islet can be impaired by 
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surgical stress (20).  
To our knowledge, this is a first report that plasma corticosterone levels may be 
modulated by IL-18 during septic conditions. This result does not conflict with a previous 
report that elevation of serum corticosterone by stress (water immersion and restraint) 
was suppressed in the absence of IL-18 in mice (21). During sepsis, the 
hypothalamic-pituitary-adrenal (HPA) axis and glucocorticoid production are initially 
activated as an inflammatory response, then become repressed later (22). Glucocorticoids 
play an anti-inflammatory role as inducers of apoptosis and inhibitors of the cellular 
proliferation of immune cells, and glucocorticoids are often administrated to septic 
patients as a supplemental therapy for adrenal insufficiency (23). Lower corticosterone 
levels in the IL-18 KO mice may have contributed to neutrophil activation and 
accumulation in the lungs of the IL-18 KO mice after CLP. This is agreement with a 
previous study that demonstrated increased lung injury in a CLP-induced rat model of 
sepsis when plasma corticosterone was reduced using metyrapone (24). On the other 
hand, rodents subjected to CLP showed high plasma corticosterone levels, indicating 
adrenal insufficiency, and some interventions that suppress the elevation of 
corticosterone improve morbidity (25,26). Because corticosterone is metabolized in the 
liver, liver damage may impair corticosterone clearance. Boonen and colleagues showed 
that critically ill patients had decreased expression of cortisol-metabolizing enzymes in 
the liver and impaired cortisol clearance (27). However, our results showed similar liver 
function in WT and IL-18 KO mice after CLP. Thus, in this model, the elevation of 
corticosterone by IL-18 may reflect suppression of the inflammatory response during 
sepsis and not adrenal insufficiency.  
We saw a trend toward improved survival in the absence of IL-18 in this CLP 
model, but could not correlate this with changes in a systemic inflammatory marker 
(IL-6), blood biochemistry, or tissue morphology. Hypoglycemia is commonly observed 
in mice with sepsis induced by CLP and may have been the cause of death in the WT mice 
(28). Hypoglycemic episodes in patients with critical illnesses have deleterious effects, 
such as systemic inflammation, neuroglycopenia, and cerebral vasodilatation, which 
contribute to mortality (29). It is likely that blood glucose in the IL-18 KO mice was not 
metabolized due to insulin resistance that developed 6 hours after CLP, which may have 
prevented hypoglycemia. Further study is needed to elucidate the contribution of IL-18 
dependent pathways to mortality. 
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It is currently debated whether IL-18 is beneficial or harmful in sepsis. We 
believe that an appropriate level of IL-18 is important to resolve sepsis. Our results 
showed that IL-18 was important for the attenuation of insulin resistance. Although 
survival tended to low in the presence of IL-18, hypoglycemia (suspected as a cause of 
death) could be avoided by monitoring blood glucose carefully in the clinical setting. 
Kinoshita and colleagues reported that IL-18 therapy was beneficial for preventing 
bacterial infection after severe critical illness (30). In addition, we demonstrated that 
endogenous IL-18 suppressed testicular germ cell apoptosis during the recovery phase of 
endotoxemia (31). In contrast, we also reported IL-18 KO mice have improved survival 
and less lung inflammation using a mouse model of lethal endotoxemia (32), and Van den 
Berghe and colleagues reported that double inhibition of IL-1 and IL-18 improved 
survival and body temperatures in several mouse models of sepsis (33). Excessive IL-18 
could lead to negative outcomes. We believe that 500-1,000 pg/mL is likely the upper 
limit of IL-18 to avoid adverse effects in mice. We are currently researching the 
relationship between IL-18 and hyperglycemia in the clinical setting using patient 
samples and have obtained encouraging results.  
Our study has some limitations. First, because we focused on glucose 
homeostasis in this study, the effects of IL-18 on the HPA axis remain unclear. IL-18 acts 
on the pituitary gland and adrenal cortex and inhibits corticotropin-releasing hormone 
release from hypothalamus (8,9,34). The mechanisms of IL-18-induced glucocorticoid 
production are still unclear and may involve the HPA axis. We are continuing to 
investigate the effects of IL-18 on the HPA axis. Second, our septic mice did not receive 
nutritional therapy or insulin therapy. Exogenous glucose infusion stimulates pancreatic 
insulin secretion from β cells, and exogenous insulin treatment is common in patients 
with sepsis-induced hyperglycemia. We cannot make clear conclusions regarding the 
influence of IL-18 on clinical outcomes based on this study.  
Conclusions 
IL-18 has an important role in suppressing insulin resistance and does not 
aggravate organ damage in mice with CLP-induced sepsis. Therefore, IL-18 is an 
important factor associated with alterations in blood glucose levels during sepsis. In 
addition, our findings provide new insight that IL-18 elevates glucocorticoid production 
during sepsis.  
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Figure Legends 
Fig. 1. Survival and plasma cytokine levels after CLP. A. Survival of mice after CLP in 
WT mice (n=16) and IL-18 KO mice (n=17). B. Alteration of plasma IL-18 after CLP. 
(n=3 at 0 hour; n=6 for other time points). C. Alteration of plasma IL-6 after CLP. (n=3 at 
0 hour; n=6 for other time points). WT CLP, filled square and solid line; KO CLP, open 
square and dashed line. *, p<0.05 vs. 0 hour by t-test. 
 
Fig. 2. Blood glucose and plasma hormones. A. Blood glucose levels. (n=6) B. Plasma 
insulin levels. (n=3 at 0 hour; n=6 for other time points) C. Plasma glucagon levels. (n=3 
at 0 hour; n=6 for other time points) D. Plasma corticosterone levels. (n=6) *, p<0.05; **, 
p<0.01 vs. WT CLP during 24 hours. ##, p<0.01 vs. sham group at each time point. WT 
sham, filled triangle and solid line; KO sham, open triangle and dashed line; WT CLP, 
filled square and solid line; KO CLP, opened square and dashed line. 
 
Fig. 3. Expression of hepatic gluconeogenic and glycolytic enzymes. A. g6pc mRNA 
expression. B. pck1 mRNA expression. C. gck mRNA expression. (n=3 at 0 hour; n=6 for 
other time points) WT CLP, filled square and solid line; KO CLP, open square and dashed 
line. 
 
Fig. 4. Akt activation. A. Akt activation in the liver. B. Quantitation of Akt 
phosphorylation in the liver. C. Akt activation in the skeletal muscle. D. Quantitation of 
Akt phosphorylation in the skeletal muscle. n=4; *, p<0.05; **, p<0.01. 
 
Fig. 5. Glucose clearance during an intraperitoneal glucose tolerance test after mild CLP. 
n=3; *, p<0.05 between WT CLP and KO CLP by two-factor ANOVA. WT CLP, filled 
square and solid line; KO CLP, open square and dashed line. 
 
Fig. 6. The effects of administering recombinant IL-18 to IL-18 KO mice. A. Blood 
glucose levels. B. Plasma insulin levels. C. Plasma corticosterone levels. (n=5) *, p<0.05 
between PBS-treated KO and rIL-18-treated KO mice by two-factor ANOVA. 
Recombinant IL-18-treated KO CLP, filled diamond and solid line; PBS-treated KO CLP, 
open diamond and dashed line. D. Akt phosphorylation in rIL-18 and PBS mice in the 
liver and skeletal muscle. n=4. 
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Supplemental Methods 
Blood analysis 
Blood samples were obtained by cardiac puncture. Plasma aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), creatinine (Cre), urea nitrogen 
(UN), lactate dehydrogenase (LD), and creatine kinase (CK) levels were measured by an 
outside laboratory (LSI Medience Corporation; Tokyo, Japan). 
 
Histological pathology 
Lung samples taken before cecal ligation and puncture (CLP) or 24 hours after 
CLP were immersed in fixative solution (4% paraformaldehyde in PBS) for 24 hours, 
dehydrated through graded alcohol dilutions, and embedded in paraffin. Tissue was 
sectioned and stained with hematoxylin and eosin (H&E) using standard protocols. The 
average alveolar septal thickness in the lungs was quantified by measuring 50 septa at 
400X magnification. Polymorphonuclear neutrophils were stained using a naphthol 
AS-D chloroacetate esterase staining kit (Sigma Diagnostics) and identified by nuclear 
morphology stained in bright red. All histological analyses were performed in 10 high 
power fields (HPFs) per sample with the samples’ identities masked. 
 
Supplemental Results 
Tissue histopathology 
 To assess the effect of interleukin (IL)-18 deletion on organ damage in multiple 
organs, biochemical tests (AST, ALT, LD, CK, Cre, UN) and morphological assessments 
were performed 24 hours after CLP operation. There were no significant differences in 
the AST, ALT, LD, CK, and Cre levels in the blood in response to either CLP operation or 
IL-18 status (Supplemental Table 1). UN levels were significantly increased by CLP both 
in the wild type (WT) and IL-18 knockout (KO) mice (Supplemental Table 1). 
Next, we examined lung morphology after CLP in the presence and absence of 
IL-18 (Supplemental Figure 1). Prior to CLP, there was no difference in lung morphology 
between WT and IL-18 KO mice. After CLP, there was neutrophil accumulation and 
septal thickening in both the WT and IL-18 KO mice, with more neutrophil accumulation 
in the lungs of the IL-18 KO mice than in the WT mice (p<0.01).  
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List of Abbreviations 
ALT  alanine aminotransferase  
ANOVA analysis of variance 
AST  aspartate aminotransferase  
CK  creatine kinase  
CLP  cecal ligation and puncture  
Cre  creatinine  
H&E  hematoxylin and eosin  
HPFs  high power fields  
IL  Interleukin  
KO  knockout  
LD  lactate dehydrogenase   
UN  urea nitrogen  
WT  wild type  
  
 
  
Supplemental Figure Legends 
Supplemental Figure. 1. Lung morphology after CLP. A. Naphtol AS-D chloroacetate 
esterase staining. Black arrowheads showed alveolar septal thickening, and black arrows 
showed a polymorphonuclear neutrophils. B. Alveolar septa thickness. C. The number of 
neutrophil per high power field. **, p<0.01 by ANOVA with the Tukey-Kramer post hoc 
test.  
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Supplemental Table 1: Blood biochemistry after induction of sepsis by CLP 
 
CK (IU/L) LD (IU/L) AST (IU/L) ALT (IU/L) Cre (mg/dL) UN (mg/dL) 
WT 
0 hours 
1295±572 463±171 257±91 20±2 0.23±0.03 28±3 
KO 
0 hours 
1303±108 483±23 307±24 38±15 0.30±0.06 26±3 
WT 
24 hours 
1502±608 634±184 503±125 86±15 0.52±0.10 85±14* 
KO 
24 hours 
3912±1009 1838±490 538±110 157±45 0.40±0.14 101±10** 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; CLP, cecal ligation and puncture; Cre, creatinine; 
KO, knockout; LD, lactate dehydrogenase; UN, urea nitrogen; WT, wild type. *, p<0.05; **, p<0.01 vs. 0 hour by ANOVA with the 
Tukey-Kramer post hoc test.
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